>“GLP-1 receptor agonists are being shown to benefit many chronic diseases over and above their effect on weight,” John Deanfield, FRCP, FESC, professor of cardiology at the Institute of Cardiovascular Sciences at University College London, told Medical News Today. “These include liver diseaseTrusted Source, kidney diseaseTrusted Source, diabetes, and neurological diseasesTrusted Source such as Parkinson’s diseaseTrusted Source. They should therefore not be labeled merely as ‘weight loss’ drugs, but as drugs that can have a direct effect to improve patients’ health.”

>Building off this research, Deanfield is the lead author of a new study recently published in the journal The LancetTrusted Source that provides further evidence of semaglutide and lowered major cardiac event risk, regardless of how much weight a person loses while taking the GLP-1 medication.

>“Semaglutide has previously been shown in the SELECT trial to significantly reduce major adverse cardiovascular events in overweight/obese patients with known heart disease but without diabetes,” Chen explained. “This study analyzed the information from the SELECT study, and found that this benefit to cardiovascular health did not depend on how overweight patients were or how much weight they lost.”

>“This interesting finding suggests that the cardiovascular benefits of semaglutide act through a biochemical mechanism not dependent simply on changing the body weight of an individual,” he continued. “This may open up other avenues of research and therapies that could improve heart health.”

https://www.medicalnewstoday.com/articles/weight-loss-drug-h...